Please note, this course is no longer eligible to receive CE credits.

Published July 29,2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers, provides background on MSI and an overview of immunotherapy treatment for MSI-high populations. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for MSI-high cancers.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

John C. Leighton, Jr., MD
Division Chair, Hematology and Medical Oncology
Einstein Healthcare Network

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe microsatellite instability and the implications for immunotherapy treatment
• Provide cancer immunotherapy treatment for microsatellite instability – high cancers
• Describe the rationale for common approaches to cancer immunotherapy
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 7/29/20 - 7/29/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2214-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.2 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

John C. Leighton, Jr., MD: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/29/20 through 7/29/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This course is no longer available for credit.

Originally published May 26, 2020 (Updated June 9. 2020)

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Hepatocellular Carcinoma (HCC), provides an overview of liver immunobiology and immunotherapeutic strategies in HCC, including checkpoint inhibition, blocking inhibitory cytokines, vaccine therapies, oncolytic viruses, and adoptive cell therapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for HCC.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Anuradha Krishnamurthy, MD
Assistant Professor of Medicine
University of Pittsburgh School of Medicine
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the characteristics of liver immunobiology
• Implement cancer immunotherapy treatment for HCC and better manage common side effects
• Describe the rationale for common approaches to cancer immunotherapy
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 5/26/20 - 5/26/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2142-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Anuradha Krishnamurthy, MD: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hepatocellular Carcinoma.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This version of the course is no longer available for credit.  To access the accredited version, go here to find the What's Next in Cancer Immunotherapy that is a CME-, CPE-, CNE-, and MOC-certified activity.

Published February 11, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, What's Next for Cancer Immunotherapy?, covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Evan J. Lipson, MD
Associate Professor, Department of Oncology
Johns Hopkins University School of Medicine

Parul Agarwal, MD
Medical Oncology Fellow
Johns Hopkins University School of Medicine
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale behind expanding the settings in which cancer immunotherapy is administered, including patients with a larger variety of tumor types and patient populations previously excluded from clinical trial participation.
• Describe the basis for novel immunotherapy drug combinations.
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 2/11/20 - 2/11/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1083-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Evan J. Lipson, MD: Consultant (Bristol-Myers Squibb, Novartis, EMD Serono, Array BioPharma, Macrogenics, Merck); Contracted Research (Bristol-Myers Squibb, Merck)
 

Parul Agarwal, MD: Nothing to Disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 2/11/20 through 2/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for What's Next for Cancer Immunotherapy?
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Published January 16, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Toxicity Management, provides an overview of clinical toxicity management for cancer immunotherapy. Both common and uncommon immune-related adverse events (irAEs) are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to manage immune-related adverse events for patients receiving cancer immunotherapy.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Morgan Gwynn, PharmD, BCOP, CPP
Melanoma and Head & Neck Oncology Clinical Pharmacist Practitioner
University of North Carolina Medical Center
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify common and uncommon immune-related adverse events associated with cancer immunotherapy
• Describe best practices for managing common side effects seen in cancer immunotherapy treatment

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 1/16/20-1/16/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1068-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hour.  Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Morgan Gwynn, PharmD, BCOP, CPP: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/16/20 through 1/16/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Toxicity Management.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Published December 17, 2019

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
 

This Basic Principles of Cancer Immunotherapy course covers the basic principles and mechanisms behind cancer immunotherapy.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses, and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Stefani Spranger, PhD
Assistant Professor of Biology
Koch Institute for Integrative Cancer Research at MIT
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy

• Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates

• Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression

• List important biomarkers for measuring the immune response

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 12/17/19-12/17/20

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-991-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.3 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Stefani Spranger, PhD: Consulting fees to Venn Therapeutic, Tango, Takeda, Replimune, Ribon, Dragonfly, Merck, Torque; Contracted Research to Takeda, Exelixis

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 12/17/19 through 12/17/20 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Basic Principles of Cancer Immunotherapy.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Firefox, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This course is no longer available for credit. Please access the updated course, Practical Barriers in Cancer Immunotherapy Treatment, which is a CME-, CPE-, CNE- and MOC-certified activity.

Published December 10, 2019

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
 

At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Amy Schippers, PA-C
Physician Assistant
St. Luke's University & Health Network
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
• Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 12/10/19-12/10/20

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-983-H04-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Amy Schippers, PA-C: Nothing to Disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 12/10/19 through 12/10/20 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Practical Barriers in Cancer Immunotherapy Treatment.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Basic Prinicples of Cancer Immunotherapy module covers the basic principles and mechanisms behind cancer immunotherapy.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Theodore F. Logan, MD

Associate Professor, Medicine

Indiana University Simon Cancer Center

Learning Objectives 

At the conclusion of this activy, the participants should be able to:

• Describe the rationale for common approaches to cancer immunotherapy

• Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates

• Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression

• List important biomarkers for measuring the immune response

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-727-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.1 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Theodore F. Logan, MD: Consulting - Prometheus Laboratories; Contracted Research - Abbott Laboratories, Abraxix BioSciences, Acceleron Pharma, Amgen, Argos Therapeutics, AstraZeneca, AVEO, BioVex, Breistol-Myers Squibb, Eisai, Lilly, GlaxoSmithKline, Roche, Immatics, Merck, Novartis, Pfizer, Synta, Threshold Pharmaceuticals, Mellennium, TRACON Pharma, Cerulean Pharma, EMD Serono, Prometheus Laboratories, Macrogenics, Peloton Therapeutics, Iovance Biotherapeutics, MedImmune, Dynavax

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The What's Next for Cancer Immunotherapy module covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Christian Capitini, MD

Assistant Professor, Medicine

University of Wisconsin Carbone Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy.
• Become familiar with clinical data on the efficacy and mechanism of action of approved therapies.

Continuing Education Information

Approximate Time to Complete: 30 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-734-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Christian Capitini, MD: Consulting Fees - Nektar Therapeutics 

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Access the updated course, Practical Barriers in Cancer Immunotherapy Treatment.

Practical Barriers in Cancer Immunotherapy Treatment, is a CME-, CPE-, CNE- and MOC-certified activity.

Please note that continuing education credit for 2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer Immunotherapy^TM) is only available through April 25, 2020.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Practical Barriers in Cancer Immunotherapy module covers practical barriers to implementing immunotherapy in a community setting (operations and reimbursement).. The module also includes a panel discussion in which experts in the field discuss common challenges they have faced including coverage and reimbursement challenges and adverse event managment.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Ryan Weight, DO, MD

Assistant Professor

University of Colorado

Monique Giordana, PharmD, BCOP

Hematology/Oncology Clinical Pharmacy Specialist 

Regions Hospital 

Lisa A. Kottschade, APRN, MSN, CNP

Associate Professor of Oncology/Nurse Practitioner

Mayo Clinic

Jodi Nordberg

Billing Operations Manager

UM Physicians

Sara Smith, PharmD, BCOP

Oncology Clinical Pharmacist

University of Minnesota Heath Maple Grove

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.

Continuing Education Information

Approximate Time to Complete: One hour and 30 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-733-H01-P) 

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.  Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Ryan Weight, DO, MD: Consulting Fees - ACCC, Castle Biosciences, Novartis; Fees for Non-CME.CE Services - Merck; Contracted Research - BMS

Monique Giordana, PharmD, BCOP: No conflict of interest to report.

Lisa Kottschade, APRN, MSN, CNP: Consulting Fees - BMS, Array BioPharma

Jodi Nordberg: Fees for Non-CME/CE Services - Genentech

Sara Smith, PharmD, BCOP: Consulting Fees - Takeda

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.